MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Equities researchers at B. Riley upped their Q2 2022 EPS estimates for MiNK Therapeutics in a research report issued on Wednesday, May 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their previous forecast of ($0.27). B. Riley also issued estimates for MiNK Therapeutics’ Q3 2022 earnings at ($0.27) EPS, Q4 2022 earnings at ($0.24) EPS, FY2022 earnings at ($0.99) EPS, FY2023 earnings at ($1.16) EPS, FY2024 earnings at ($1.45) EPS, FY2025 earnings at ($1.51) EPS and FY2026 earnings at ($1.28) EPS.
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02).
Shares of INKT stock opened at $1.29 on Monday. MiNK Therapeutics has a one year low of $1.25 and a one year high of $22.16. The company has a 50 day moving average price of $2.42 and a 200 day moving average price of $5.68.
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in MiNK Therapeutics during the 4th quarter valued at $46,000. State Street Corp acquired a new stake in shares of MiNK Therapeutics during the fourth quarter worth $53,000. Invesco Ltd. acquired a new stake in shares of MiNK Therapeutics in the 4th quarter worth about $94,000. Geode Capital Management LLC acquired a new stake in shares of MiNK Therapeutics in the 4th quarter worth about $105,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of MiNK Therapeutics in the 4th quarter worth about $157,000. Hedge funds and other institutional investors own 3.99% of the company’s stock.
About MiNK Therapeutics (Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials.
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.